ALTER Stock Overview
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Theradiag SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.26 |
| 52 Week High | €2.39 |
| 52 Week Low | €1.18 |
| Beta | -0.27 |
| 1 Month Change | -5.97% |
| 3 Month Change | -43.75% |
| 1 Year Change | -44.86% |
| 3 Year Change | -51.91% |
| 5 Year Change | 35.78% |
| Change since IPO | -77.74% |
Recent News & Updates
Slammed 26% Theradiag SA (EPA:ALTER) Screens Well Here But There Might Be A Catch
Oct 04
Theradiag (EPA:ALTER) Might Have The Makings Of A Multi-Bagger
Oct 03Shareholder Returns
| ALTER | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -4.9% | 0.003% | -1.7% |
| 1Y | -44.9% | 23.6% | -4.8% |
Return vs Industry: ALTER underperformed the French Medical Equipment industry which returned 5.2% over the past year.
Return vs Market: ALTER underperformed the French Market which returned 12.7% over the past year.
Price Volatility
| ALTER volatility | |
|---|---|
| ALTER Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALTER's share price has been volatile over the past 3 months.
Volatility Over Time: ALTER's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 61 | Simon Daviere | www.theradiag.com |
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer.
Theradiag SA Fundamentals Summary
| ALTER fundamental statistics | |
|---|---|
| Market cap | €16.44m |
| Earnings (TTM) | €421.92k |
| Revenue (TTM) | €13.51m |
39.0x
P/E Ratio1.2x
P/S RatioIs ALTER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTER income statement (TTM) | |
|---|---|
| Revenue | €13.51m |
| Cost of Revenue | €7.24m |
| Gross Profit | €6.26m |
| Other Expenses | €5.84m |
| Earnings | €421.92k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 46.37% |
| Net Profit Margin | 3.12% |
| Debt/Equity Ratio | 17.1% |
How did ALTER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/21 12:24 |
| End of Day Share Price | 2023/12/21 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Theradiag SA is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pierre Boucheny | Kepler Cheuvreux |
| Arnaud Guérin | Portzamparc BNP Paribas |